Sir, Tenofovir alafenamide is a prodrug of tenofovir-diphosphate, which has demonstrated high efficacy and tolerability in the treatment of people living with HIV/AIDS (PLWHA) when used in combination with other antiretroviral agents. 1, 2 It is currently recommended for the treatment of naive and experienced patients by national and international guidelines, including patients with HIV/HBV coinfection. 3 Thanks to lower circulating levels of tenofovir, but higher intracellular metabolism of tenofovir-diphosphate, tenofovir alafenamide ensures both a higher antiviral activity at lower doses than its parent drug 4 and a better safety profile compared with tenofovir disoproxil fumarate. Tenofovir alafenamide may play a key role in decreasing bone and renal ART-related toxicity in PLWHA. 5 In an ideal world, all tenofovir disoproxil fumarate regimens should be switched to tenofovir alafenamide, but, mainly due to market availability of generic tenofovir disoproxil fumarate, cost poses a major obstacle to switching strategies. It is therefore important to build a tenofovir alafenamide agenda in order to prioritize the patients who may most benefit from it.
Randomized clinical studies have proven the benefit of a 'reactive' switching strategy from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with pre-existing renal or bone metabolism impairments. 6 Furthermore, expert opinion recommends a 'proactive switch' strategy in more vulnerable groups, including older people, patients with osteoporotic fractures or progressive loss of kidney function, post-menopausal women or even 'naive' patients as a whole, to avoid the initial 3%-4% bone loss expected in patients starting regimens containing tenofovir disoproxil fumarate.
What has not been mentioned so far is that people who may benefit most from switching to tenofovir alafenamide are ARTexperienced HIV-infected people who are currently taking neither tenofovir disoproxil fumarate nor abacavir. These patients tend to receive a highly disproportionate number of drug combinations, a real jungle of prescriptions usually chosen by physicians with no empirical support from clinical studies. From this perspective, the impact of tenofovir disoproxil fumarate in the HIV treatment armamentarium goes beyond its capacity to reduce drug toxicities. In fact, it reduces the number of mono or dual ART regimens. These non-conventional ART regimens may represent up to 30% of ART prescriptions in people with comorbidities aggregating in complex multi-morbidity pictures. In this setting, the choice of regimen is mainly driven by concerns about what to avoid, rather than what to choose. Most of the time, both tenofovir disoproxil fumarate and abacavir are avoided in order to escape renal/bone and cardiovascular toxicities, respectively.
In a recent experience from the GEPPO cohort including 1222 HIV-infected patients aged 65 years, in which multi-morbidity was present in 64% and poly-pharmacy in 37% of the patients, mono/dual therapy was used to treat 32% of the patients. What was really impressive was that among the 384 patients undergoing mono/dual therapy there were 68 different ART regimens: the same ART regimen is not shared by more than 5.6 patients, on average. 7 People who may benefit most from tenofovir alafenamide include patients currently undergoing mono/dual ART regimens. These may 'return' to a conventional triple regimen supported by randomized clinical trials, which is probably safer for the patients and more secure for the prescribers.
Should mono/dual regimens therefore be abandoned? Of course not, and the theoretical approach of induction/maintenance therapy is still very logical and virologically oriented. Moreover, preliminary results from the Gemini 8 and Sword 9 trials demonstrate that dual, non-boosted regimens can result in exceptional virological success not inferior to triple regimens in treatment-naive and treatment-experienced patients, respectively. Unfortunately, these 'strategic studies' will remain in their infancy unless innovative clinical endpoints are defined.
We all agree that virological non-inferiority is a prerequisite and not the appropriate outcome of these studies. The reason for switching to mono/dual regimens is to reduce NRTI or PI toxicities, thereby improving single-organ conditions. Nevertheless, with particular regard to the HIV ageing scenario, the benefit of a regimen must be identified beyond a diseasebased conceptualization. Geriatricians teach us that the most important consideration for an older person is likely to be their functioning, rather than the presence or absence of disease.
Comprehensive assessments of functioning in older age also serve as much better predictors of survival and other outcomes than the presence of disease or even the extent of comorbidities. Geriatrics-focused research endpoints, including frailty, geriatric syndromes and physical function, which have been used in 'cardiogeriatrics' or 'oncogeriatrics', will hopefully be also used to assess the benefit of ART strategies, comparing single-tablet regimens with less drug regimen. This 'game changer' in clinical studies will take some time, while right now a significant reduction in the jungle of ART prescriptions is taking place, with clear benefits for both patients and prescribers.
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